Article Text
Therapeutics
Systematic review and meta-analysis
Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma
Statistics from Altmetric.com
Footnotes
-
Correction notice This article has been corrected since it was published Online First. The word ‘exacerbation’ has been corrected to ‘exacerbations’ in the article title.
-
Competing interests NCT has participated in advisory boards and/or received consultancy fees from Asmacure, Chiesi and Respivert. He has received lecture fees from Boston Scientific, Chiesi, GlaxoSmithKline and Novartis, and industry-sponsored grant funding to the University of Glasgow from AstraZeneca, Boston Scientific, Genentech, GlaxoSmithKline, Novartis, Pfizer and Synairgen for participating in clinical trials.